Physician profile
Jordon Grube
NPI 1114346566
$8,696.36
in general payments reported to CMS, 2019-2025
8 companies · $4,275 in 2025
The $4,275 reported for 2025 was more than what 95% of Otolaryngology/Facial Plastic Surgery providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.98 · 2022: $915 · 2023: $932 · 2024: $2,541 · 2025: $4,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,400 · Food and Beverage: $3,347.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,400.00 |
| Food and Beverage | $3,347.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $7,184.01 | 2022-2025 | |
| Medtronic, INC. | $472.17 | 2022-2025 | Straightshot, Sinuva, Propel |
| Acclarent, INC | $340.29 | 2023-2024 | Trudi Nav Cable |
| Stryker Corporation | $295.48 | 2022-2024 | Na |
| Integra Lifesciences Corporation | $202.77 | 2024-2025 | Inspira Air, Acclarent Aera, Relieva Spinplus Nav |
| Optinose US, INC. | $134.83 | 2024 | |
| Medtronic USA, INC. | $33.98 | 2019 | |
| Genzyme Corporation | $32.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordon Grube listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.